Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Found 6,914 clinical trials

P Pamela Gerecht, PhD

Adaptive DBS to Offset STN Dysregulation During Exercise in PD

The investigators conduct a prospective study to evaluate the effects of exercise on Parkinson's Disease brain biomarkers detected with the PerceptTM PC neurostimulator.

20-70 years All Phase N/A
P Pierre Cougoul, MD

Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during …

18 years and older All Phase N/A
B Büşra Şirin Ahısha, MD

Caregiver Burden in Parkinson's Disease

Primary caregivers of patients diagnosed with idiopathic Parkinson's disease will be included in the study. A total of 43 participants will be recruited. At the beginning of the study, demographic data and clinical characteristics of the patients, including disease stage, history of falls, presence of fractures, presence and severity of …

40-80 years All Phase N/A
Z Zhao

TSPO PET in the Evaluation of Neuroinflammation in Patients with Multiple System Atrophy

The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis of MSA disease.

35-80 years All Phase N/A
Z Zhao

Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis in MSA.

35-80 years All Phase N/A
C Carmela Tartaglia, MD

Diagnosing Frontotemporal Lobar Degeneration

To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes

18-90 years All Phase N/A
E Erika Franzén, PhD

Physical Activity in Persons With Parkinson's Disease

Parkinson's disease (PD) is a leading neurodegenerative health condition in Sweden and a public health concern. Although no cure exists, functional independence and participation in society remain top priorities, and can be achieved through targeted physical activity (PA) interventions. To date, few longitudinal cohort studies have been conducted, using PA …

All Phase N/A

Training of Nursing Home Professionals and Quality of Life of Residents With Parkinson's Disease

The complexity of medication treatments and the diversity of symptoms in Parkinson's disease (PD) require healthcare professionals to have specific knowledge of the disease in order to manage symptoms optimally and on an individualized basis. This becomes even more important as the disease progresses due to the evolution of symptoms …

18 years and older All Phase N/A
J Jiping Li, MD

Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by both motor and non-motor symptoms. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectively alleviates motor symptoms; however, non-motor symptoms such as sleep disorders significantly impair patients' quality of life. While preliminary evidence suggests DBS may improve sleep, the underlying neural …

19-80 years All Phase N/A

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa/ foslevodopa is in treating …

18-64 years All Phase N/A

Simplify language using AI